Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Xeltis Bioabsorbable Pulmonary Valved Conduit Early Feasibility Study (Xplore2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03022708
Recruitment Status : Recruiting
First Posted : January 16, 2017
Last Update Posted : July 4, 2018
Sponsor:
Information provided by (Responsible Party):
Xeltis

Brief Summary:
This is a multi-center prospective, single-arm, non-randomized, open label study to assess feasibility of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring Right Ventricular Outflow Tract correction or reconstruction due to congenital heart malformations.

Condition or disease Intervention/treatment Phase
Heart Defect, Congenital Device: Xeltis Bioabsorbable Pulmonary Valved Conduit Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
Actual Study Start Date : May 8, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Xeltis Bioabsorbable Pulmonary Valved Conduit

The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.

The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:

  • Tetralogy of Fallot
  • Truncus Arteriosus
  • Pulmonary Atresia
  • Transposition of Great Arteries with Ventricular Septal Defect
  • Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes

In addition, the PV conduit can be used for the following indications:

  • replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).
  • Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve.
Device: Xeltis Bioabsorbable Pulmonary Valved Conduit
Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit




Primary Outcome Measures :
  1. Freedom of device related death due to device failure at 6 months follow up post implantation [ Time Frame: 6 months ]
    Measured by the fact that the patient is still alive at the time of the 6 month FU visit

  2. Freedom of device related death at 12 months follow-up [ Time Frame: 12 months ]
    Measured by the fact that the patient is still alive at the time of the 12 month FU visit

  3. Freedom of re-operation or re-intervention at 6 months follow-up due to device failure [ Time Frame: 6 months ]
    Measured by the fact that the patient did not have a reoperation or reintervention during the first 6 months


Secondary Outcome Measures :
  1. Overall rate of mortality at 60 months follow up post implantation [ Time Frame: 60 months ]
    Measured by the fact that the patient is still alive at the time of the 60 month FU visit

  2. Overall rate of subjects who require reoperation or reintervention due to device failure at 12 months [ Time Frame: 12 months ]
    Measured by the fact that the patient did not have a reoperation or reintervention during the first 12 months

  3. Overall rate of subjects with a mean pressure gradient across the area of conduit implantation (RV to PA) of less than 40 mm Hg at 6 and 12 months follow up [ Time Frame: 6 and 12 months ]
    Measured with echocardiography at 6 and 12 months follow up.

  4. Overall rate of subjects with pulmonary regurgitation of equal or less than moderate at 6 and 12 months follow up [ Time Frame: 6 and 12 months ]
    Measured with echocardiography at 6 and 12 months follow up.


Other Outcome Measures:
  1. Measurement of growth of the conduit in pediatric population at 6, 36, 48 and 60 months [ Time Frame: Up to 60 months ]
    Measured with echocardiography at 6, 36, 48 and 60 months follow up.

  2. Overall satisfaction of the implanting surgeon of the implantation procedure of the Bioabsorbable pulmonary valved conduit [ Time Frame: Day 0 - Implant ]
    Measured with a questionnaire given to the implanting surgeon at the time of implantation of the PV conduit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient requiring RVOT reconstruction, suitable for 16 mm or 18 mm valved conduit.
  2. Male or Female.
  3. Age > 2 years and < 22 years.
  4. Right Ventricular to Pulmonary Artery peak gradient > 35mm Hg or moderate or severe Pulmonary regurgitation (≥3+), or have both (except for the patients undergoing a Ross procedure)
  5. The patient, and the patient's parent / legal representative where appropriate, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent by signing the approved informed consent form.
  6. The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.

Exclusion Criteria:

  1. Need for or presence of prosthetic heart valve at other position.
  2. Need for concomitant surgical procedures (non-cardiac).
  3. Patients with previously implanted pacemaker (including defibrillators), or mechanical valves.
  4. Active infection or requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics) or viral infection.
  5. Active endocarditis.
  6. Leukopenia, defined as White Blood cell Count < than:

    • 2-12 years: 5.0 ×103 /μL
    • 12 years - Adult:
    • Male: 4.5×103 /μL
    • Female: 4.5 ×103 /μL
  7. Acute or chronic anemia, defined as Hemoglobin < than:

    • 2-12 years 11.5 g /dl
    • 12-18:
    • Male: 13 g /dl
    • Female 12 g /dl
    • Adult:
    • Male: 13.5 g /dl
    • Female: 12 g /dl Patients can be transfused to meet eligibility criteria
  8. Thrombocytopenia, defined as Platelet count < than:

    • 150,000/mm3 Patients can be transfused to meet eligibility criteria
  9. Severe chest wall deformity, which would preclude placement of the PV conduit.
  10. Pulmonary hypertension (≥ half of systemic systolic pressure)
  11. Right ventricular outflow tract aneurysm.
  12. Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials. .
  13. Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs.
  14. Subject has chronic inflammatory / autoimmune disease.
  15. Need for emergency cardiac or vascular surgery or intervention.
  16. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year.
  17. Currently participating, or participated within the last 30 days, in an investigational drug or device study.
  18. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
  19. Pregnancy.
  20. Females who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
  21. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03022708


Contacts
Layout table for location contacts
Contact: Eliane Schutte 8668188461 eliane.schutte@xeltis.com
Contact: Luc Verhees 8668188461 Luc.verhees@xeltis.com

Locations
Layout table for location information
United States, California
Children's Hospital of Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Ana Munoz       anamunoz@chla.usc.edu   
Principal Investigator: Cynthia Herrington, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Meredith Wilkes       meredith.wilkes@childrenscolorado.org   
Principal Investigator: Max Mitchell, MD         
United States, Georgia
Children's Healthcare of Atlanta Recruiting
Atlanta, Georgia, United States, 30322
Contact: Janet Fernandez       Janet.Fernandez@choa.org   
Principal Investigator: Kirk Kanter, MD         
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Michele Borisuk       Michele.Borisuk@cardio.chboston.org   
Principal Investigator: Christopher Baird, MD         
United States, New York
New York Presbyterian Hospital - Columbia University Recruiting
New York, New York, United States, 10032
Contact: Kydanis Clase       kc3020@cumc.columbia.edu   
Principal Investigator: Emile Bacha         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Katy Fischesser       HIRCRegulatory@cchmc.org   
Principal Investigator: James Tweddell, MD         
United States, Pennsylvania
The Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Nancy Burnham       BURNHAMN@email.chop.edu   
Principal Investigator: J William Gaynor, MD         
Children's Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Tamara Mailhe       maihlets@upmc.edu   
Principal Investigator: Victor Morell, MD         
Sponsors and Collaborators
Xeltis
Investigators
Layout table for investigator information
Study Director: Eliane Schutte Xeltis Inc

Layout table for additonal information
Responsible Party: Xeltis
ClinicalTrials.gov Identifier: NCT03022708     History of Changes
Other Study ID Numbers: XEL-CR-03
First Posted: January 16, 2017    Key Record Dates
Last Update Posted: July 4, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Defects, Congenital
Congenital Abnormalities
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases